Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. scores highest on Nitro (70) and lowest on Price (7). Its PosiPenta is 49.45 out of 100, around the middle of similar companies.
On the Penta Grid this week, Tarsus Pharmaceuticals, Inc. is Grid #294 of 837 in the Healthcare sector in United States, and Grid #1,945 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 49.45 | 7 | 53 | 70 | 54 | 62 |
| Celcuity Inc. | 31.42 | 0 | 47 | 33 | 4 | 72 |
| Warby Parker Inc. | 54.64 | 10 | 87 | 75 | 52 | 49 |
| Viking Therapeutics, Inc. | 36.21 | 9 | 21 | 38 | 54 | 60 |
| Parabilis Medicines, Inc. | 42.70 | 23 | 39 | 31 | 60 | 60 |
| Enliven Therapeutics, Inc. | 50.62 | 21 | 25 | 65 | 75 | 67 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -63.03 |
| P/B ratio | 9.19 |
EEarnings
| Trailing EPS | ₹-102.29 |
| Forward EPS | ₹-47.36 |
NNitro
| Price | 6447.25 |
| 52-week high | 8669.26 |
| 52-week low | 5104.19 |
| Fall from 52-week high | 25.6% |
TTorque
| Return on equity (ROE) | -13.68% |
| Debt-to-equity | 0.26 |
AAnchor
| Beta (price swings) | 0.45 |
| Market cap | ₹30,167 Cr |
| Insider holding | 2.69% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Tarsus Pharmaceuticals, Inc.'s PosiPenta score?
Tarsus Pharmaceuticals, Inc.'s PosiPenta is 49.45 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Tarsus Pharmaceuticals, Inc. stand on the Penta Grid?
On the Penta Grid this week, Tarsus Pharmaceuticals, Inc. is Grid #294 of 837 in the Healthcare sector in United States, and Grid #1,945 of 4,000 in United States.
Which PosiPenta pillar is strongest for Tarsus Pharmaceuticals, Inc.?
Nitro (momentum), with a score of 70 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Tarsus Pharmaceuticals, Inc.?
Price (valuation), with a score of 7 out of 100: much weaker than most similar companies.
Has Tarsus Pharmaceuticals, Inc.'s PosiPenta changed since last week?
Yes, it rose 0.58 points, from 48.87 to 49.45.
PositoAI is for research and education only and is not investment advice.